Pembrolizumab as adjuvant therapy in non-small-cell lung cancer. Uprety D. Lancet Oncol 2022;23:e527.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Uprety D. Pembrolizumab as adjuvant therapy in non-small-cell lung cancer. Lancet Oncol 2022;23:e527.
PMID: 36455576